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Key Points
We conducted the first exome-wide association study between germ line variant genotype and
survival outcomes after unrelated-donor BMT.
A number of novel genes were found to significantly affect survival outcomes.

Abstract
Although survival outcomes have significantly improved, up to 40% of patients die within 1 year of HLAmatched unrelated-donor blood and marrow transplantation (BMT). To identify non-HLA genetic
contributors to mortality after BMT, we performed the first exome-wide association study in the
DISCOVeRY-BMT cohorts using the Illumina HumanExome BeadChip. This study includes 2473 patients
with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome and 2221 10/10
HLA-matched donors treated from 2000 to 2011. Single-variant and gene-level analyses were performed
on overall survival (OS), transplantation-related mortality (TRM), and disease-related mortality (DRM).
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC5981168/?report=printable
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Genotype mismatches between recipients and donors in a rare nonsynonymous variant of testis-expressed
gene TEX38 significantly increased risk of TRM, which was more dramatic when either the recipient or
donor was female. Using the SKAT-O test to evaluate gene-level effects, variant genotypes of OR51D1 in
recipients were significantly associated with OS and TRM. In donors, 4 (ALPP, EMID1, SLC44A5, LRP1),
1 (HHAT), and 2 genes (LYZL4, NT5E) were significantly associated with OS, TRM, and DRM,
respectively. Inspection of NT5E crystal structures showed 4 of the associated variants affected the enzyme
structure and likely decreased the catalytic efficiency of the enzyme. Further confirmation of these
findings and additional functional studies may provide individualized risk prediction and prognosis, as
well as alternative donor selection strategies.

Visual Abstract
Introduction
Blood and marrow transplantation (BMT) is an effective treatment for many life-threatening malignant
hematologic diseases. Survival after BMT has increased dramatically over the past 2 decades, as a result of
improvements in patient selection, high-resolution HLA typing, better supportive care, and infection
prophylaxis.1-3 The most established genetic predictors of BMT survival reside in the major
histocompatibility complex (MHC) region, which encodes the HLAs. To improve survival, the current
recommendation is to select a donor who matches the recipient in 4 HLA genomic loci (HLA-A, -B, -C,
and -DRB1) as well as other characteristics, including HLA-DP typing, sex, blood type, and
cytomegalovirus status.4-7 Numerous candidate gene studies have investigated non-HLA genomic loci that
are associated with survival after allogeneic BMT.8 However, these studies have generated inconsistent
results, likely because of sample size limitations and heterogeneity of disease and disease status, recipientdonor relationship, degree of HLA match, and other factors.8 As part of the DISCOVeRY-BMT study
(Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after
BMT),9,10 we conducted the first exome-wide association study of mortality after BMT. Exome-wide
association studies analyze functional coding variants, including those that are rare in the population,
under the hypothesis that rare genetic variants may convey larger effects than common variants.11,12 Our
study is the first analysis of the rare variant contribution to BMT survival outcomes, from which we
identified both missense variants and novel genes associated with patient survival after HLA-matched
unrelated-donor (URD) allogeneic BMT.

Methods
Study population
All participants were from the DISCOVeRY-BMT study.9,10 DISCOVeRY-BMT consists of 2 wellcharacterized cohorts (cohort 1 and cohort 2; Table 1). Both cohorts include patients who were treated with
URD BMT for ALL, AML, and MDS and their 8/8 HLA-matched (high-resolution HLA-A, -B, -C, and DRB1 loci) unrelated donors. Cohort 1 includes patients who underwent 10/10 HLA-matched (highresolution HLA-A, -B, -C, -DRB1, and -DQB1 loci) URD BMT from 2000 to 2008 and reported to the
Center for International Blood and Marrow Transplant Research, whereas cohort 2 includes patients who
underwent 10/10 HLA-matched URD BMT from 2009 to 2011 or 8/8 (but <10/10) HLA-matched URD
BMT from 2000 to 2011 and reported to Center for International Blood and Marrow Transplant Research.
The exome-wide association study was restricted to patients who received a 10/10 HLA match in cohort 1
or 2. Causes of death were adjudicated by an expert panel as previously described.9 All patients and
donors provided written informed consent for their clinical data to be used for research purposes and were
not compensated for their participation. This study was reviewed and approved by the Roswell Park
Cancer Institute Institutional Review Board. All patient data were deidentified.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC5981168/?report=printable
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Genotyping and quality control
All samples were genotyped using Illumina HumanExome-12 v1.1 BeadChip. We used the Optimal
Sample Assignment Tool to randomly assign samples to plates for genotyping to eliminate batch effects
and any potential confounding factors.13 Samples and variants that were successfully genotyped
underwent stringent sample-level and variant-level quality control (QC). In sample-level QC, samples
were removed if the missing rate was ≥2%, if the typed and reported sex did not match, if there were
abnormal inbreeding coefficients, or if cryptic relatedness was present. Population outliers were removed
using EIGENSTRAT.14 Because of the low number of non-European populations in our study cohort, our
analyses were carried out only in recipients of European descent and their donors. After sample-level QC,
1970 recipients and 1741 donors were retained in cohort 1 and 503 recipients and 480 donors were
retained in cohort 2. In variant-level QC, variants were removed if the missing rate was ≥2%, if there was
≥1 Mendelian error in HapMap trios included in our genotyping, or if variants violated Hardy-Weinberg
equilibrium (P < 1 × 10−6) or were discordant between duplicate samples. In total, 240 653 variants in
recipients and 240 640 variants in donors of cohort 1 successfully passed QC, and 240 603 variants in
recipients and 240 573 variants in donors of cohort 2 successfully passed QC. Cluster plots for all variants
reported herein were manually inspected for quality.
Statistical analysis
Because the 2 cohorts differed on several patient, disease, and treatment characteristics, we used a 2-stage
study design (supplemental Figure 1, available on the Blood Web site).
Single-variant analysis
The likelihood ratio test (LRT) was used to analyze single-variant association between survival outcomes
of recipients (overall survival [OS]/treatment-related mortality [TRM]/disease-related mortality [DRM])
and the variant genotypes of either recipients or corresponding donors while controlling for additional
covariates of recipients: age at BMT, disease diagnosis (AML/ALL/MDS), disease status at BMT, cell
source (peripheral blood/marrow), and all principal components deemed significant by the Tracy-Widom
statistic derived from EIGENSTRAT. Singleton variants and nonautosome variants were eliminated from
the single-variant association analysis. We used cumulative incidence functions to handle the competing
risks of TRM and DRM in association analysis. We also used LRT to evaluate the association between
recipients’ survival outcomes and the recipient-donor allele mismatches for each variant, defined as the
absolute difference in allele dosage between each recipient-donor pair. The survival and cmprsk packages
in R software were used to perform single-variant analysis within each cohort, and the meta-analysis of
both cohort 1 and cohort 2 was performed using a fixed-effects model in METAL.15 For each outcome,
variants with a suggestive association (P < 1 × 10−3) in cohort 1 were entered into the fixed-effects model
meta-analysis performed using METAL.15 Significance level was determined using a Bonferroni
correction for the effective number of independent tests after adjusting for the correlation between
variants,16,17 which yielded Pmeta ≤ 1.32 × 10−6 to reach exome-wide significance. To evaluate whether
sex modified the association between TRM and recipient-donor allele mismatches in rs200092801, we
added an interaction term between the sex indicator variable (for male-male recipient donor pairs) and the
allele mismatches in rs200092801 to the competing risk model and used an LRT to assess the significance
of the interaction term.
Gene-based analysis
The optimal sequence kernel association (SKAT-O) test18 was used to analyze the gene-level association
between recipients’ survival outcomes (OS/TRM/DRM) and the genotypes of either recipients or the
corresponding donors using the same covariates as the single-variant analysis. In gene-level analysis, we
adopted a cause-specific hazard model to handle the competing risk situation in association analysis of
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC5981168/?report=printable
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TRM and DRM. The skatMeta and survival packages in R software were used for running the SKAT-O
tests. We removed variants with minor allele frequency >1% from the corresponding cohorts and only kept
missense and nonsense variants for the analysis, which resulted in >12 000 genes tested in recipients and
donors. In the discovery stage, we performed SKAT-O tests on genes with ≥2 variants in cohort 1. The
genes with P < 1 × 10−3 were further evaluated in a meta-analysis that integrated genotypes from both
cohort 1 and cohort 2. We set overall exome-wide significance at Pmeta < 4.10 × 10−6 after Bonferroni
correction for the total number of genes tested.
MHC binding prediction
MHC binding affinity was predicted across all possible 8- to 15-mer peptides surrounding the rs200092801
variant in TEX38 and the corresponding wild-type peptides using NetMHCpan 4.0.19 These tiled peptides
were analyzed for their binding affinities (IC50 in nM units) to each class I HLA allele. An IC50 value of
<150 nM was considered a predicted strong binder, and IC50 >500 nM was considered a nonbinder.
Crystal structure analysis
The crystal structures of NT5E were obtained from the Protein Data Bank (Protein Data Bank codes:
4H2G [open state], 4H2I [closed state]). Visualization was performed using PyMOL Molecular Graphics
System, version 1.8 (Schrödinger, https://www.schrodinger.com/suites/pymol).
Kaplan-Meier plots
Kaplan-Meier (KM) plots were used to show the impact of the gene on survival outcomes. For the KM
plots, we assumed variant impact on survival was exchangeable, with each variant contributing equally in
magnitude and direction. Therefore, we only generated the KM plots when the assumption of directionality
was not violated based on the variant weights from SKAT-O.

Results
Single-variant association analyses
The single-variant association analyses of recipient (only) genotypes and donor (only) genotypes did not
yield any statistically significant variants. In the analysis of recipient-donor variant allele mismatching,
only 1 variant in TEX38 (exm56988, rs200092801) was statistically significant in the single-variant
analyses (Table 2; Figure 1; supplemental Figure 2). TRM in recipients was found to be significantly
associated with the allele mismatches between recipients and donors of rs200092801 (Pmeta = 3.51 ×
10−7). Recipients whose genotypes differed from their donors’ were much more likely to die as a result of
TRM than those who had genotypes that were identical to their donors’, but there was no impact of this
variant on DRM (supplemental Table 1; supplemental Figure 3). This association between TRM and allele
mismatches at rs200092801 likely resulted from the consistent trend of increasing TRM risk by the minor
allele of rs200092801 in both recipient and donor genotypes (supplemental Table 1; supplemental Figure
3). rs200092801 is a rare nonsynonymous variant and was observed only in recipients of cohort 1 with
minor allele frequency of 0.3%. TEX38 is highly and preferentially expressed in the testes, but its function
is not yet understood. Given the strong expression of TEX38 in the testes, the 4 combinations of recipientdonor sex (male donor to female recipient [M→F], male donor to male recipient [M→M], female donor to
male recipient [F→M], and female donor to female recipient [F→F]) were assessed for an interaction with
rs200092801 for TRM. Recipient-donor pairs were stratified based on these 4 combinations, and variant
association was analyzed with a competing risk model. Recipient hazard of death resulting from TRM was
considerably higher when either the recipient or donor was female and recipient and donor were
mismatched at rs200092801, compared with male recipients with male donors who were mismatched at
this variant (Figure 2). Specifically, among recipients who were mismatched with their donors at
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC5981168/?report=printable
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rs200092801, every female recipient and every recipient with a female donor died as a result of TRM,
compared with 44% patients in the M→M group who died as a result of TRM. The median survival times
for recipient-donor pairs mismatched at rs200092801 for F→F, F→M, and M→F were 1.1, 0.9, and 4.4
months, respectively; the median survival time for M→M was 5.9 months. The interaction between
recipient-donor sex combination and recipient-donor allele mismatch at rs200092801 were tested in the
competing risk model, and recipient-donor sex was found to significantly modify the association between
TRM and recipient-donor allele mismatches at rs200092801 (Pinteraction = 4.6 × 10−3).
Suspecting TEX38 as a male testis antigen, we further explored whether rs200092801 could affect the
recognition of the antigen by HLA class I molecules. rs200092801 causes an amino acid change (P178S)
in TEX38 protein. Interestingly, we identified 3 peptides containing the mutant amino acid S (mutant
peptides) that were predicted to strongly bind with various HLA class I alleles, whereas the corresponding
peptides containing the wild-type amino acid P (wild-type peptides) had no binding (supplemental Table
2). Therefore, it is possible that the C to T nucleotide change of rs200092801 in TEX38 results in a mutant
peptide that can be presented by MHC class I molecules to immune cells to trigger downstream immune
response and TRM. Among the 18 recipient-donor pairs with allele mismatches at rs200092801, there
were 11 pairs carrying the HLA class I alleles that were predicted to strongly bind with the mutant peptides
but not the wild-type peptides. Notably, recipients in 9 (82%) of these 11 pairs died as a result of TRM,
compared with 4 TRM events (57%) in the 7 remaining pairs, which suggests a positive link between
TRM risk and rs200092801-specific strong binding of TEX38 peptide with MHC class I molecules.
Gene-level association analyses
Recipient gene-level associations with OS, TRM, and DRM after BMT. One gene, OR51D1, which

encodes an olfactory receptor (OR), was significantly associated with OS (Pmeta = 9.48 × 10−7). Six
nonsynonymous variants in OR51D1 contributed to the association signal (Table 3); all are rare in the
DISCOVeRY-BMT cohorts and in the general European population. Importantly, OR51D1 was also the
only gene significantly associated with TRM (Pmeta = 1.05 × 10−6), with the same 6 variants contributing
to the associations signal. This gene was not associated with DRM (Pmeta = .07), which means the genetic
contribution of OR51D1 to TRM translates to a significant effect on OS. An advantage of SKAT-O is that
it allows individual variants to have different directions and magnitudes of effect. In association analysis of
OS, the minor alleles of 5 of the 6 variants contributed to better survival, whereas in association analysis of
TRM, the minor alleles of all 6 variants contributed to better survival (supplemental Table 3). In an
intuitive visualization of the impact of the gene on survival outcomes, supplemental Figure 4 compares
recipients who carried a minor allele at any of the 6 variants and those who did not. There was a protective
effect of OR51D1 variants in recipients that reduced the risk of TRM; none of the recipients carrying these
6 minor alleles died as a result of TRM, although there were some deaths attributable to DRM. We did not
find any recipient genes to be significantly associated with DRM.
Donor gene-level associations with OS after BMT. Four genes in donors were significantly associated

with OS: ALPP, EMID1, SLC44A5, and LRP1 (Table 4; supplemental Tables 4 and 5). ALPP encodes an
alkaline phosphatase, and 3 ALPP variants contributed to the gene-level association. All 14 recipients
whose donors carried the minor alleles of these 3 variants survived the first year after BMT (supplemental
Figure 5). Two donor variants in EMID1 affected recipient OS; 1 was protective, and the other was
detrimental (supplemental Table 5). SLC44A5 is a member of the solute carrier gene family, and 2 donor
variants in this gene contributed to its association with OS. Recipients whose donors carried the minor
alleles of the 2 variants were found to have worse survival than recipients whose donors were noncarriers
(supplemental Figure 6). LRP1 (low-density lipoprotein receptor-related protein 1) encodes an endocytic
receptor involved in several cellular processes, including intracellular signaling, lipid homeostasis, and
clearance of apoptotic cells. Within LRP1, 27 variants contributed to the association of the gene with OS;
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however, the effects of the individual variants included some that were protective and some that were risk
conveying (supplemental Table 5). None of these 4 genes were significantly associated with TRM or
DRM.
Donor gene-level associations with TRM and DRM after BMT. The gene HHAT was significantly

associated with TRM, whereas 2 other genes, LYZL4 and NT5E, were significantly associated with DRM (
Table 4; supplemental Tables 6-9). HHAT (hedgehog acyltransferase) encodes an enzyme that catalyzes Nterminal palmitoylation of sonic hedgehog (SHH) and is required for SHH signaling. SHH is known to
affect T-cell proliferation and maturation and maintain survival and growth of CML progenitor cells.20,21
Six HHAT variants contributed to its association with TRM; 5 of the variants had a protective effect in
both cohorts, with 1 variant showing an inconsistent direction of effect between cohorts (supplemental
Tables 6 and 7). LYZL4 (lysozyme-like 4) belongs to a family of lysozyme-like genes, and lysozymes play
a mainly protective role in host defense. Three LYZL4 variants contributed to the association of the gene
with DRM; 2 variants increased risk of DRM, and 1 variant was protective (supplemental Tables 8 and 9).
The encoded protein of NT5E, ecto-5′-nucleotidase or CD73, catalyzes the conversion of extracellular
nucleotides to membrane-permeable nucleosides. A total of 6 variants contributed to the association of
NT5E with DRM, and all exerted a protective effect (supplemental Table 9). None of the recipients whose
donors carried the minor alleles of these 6 variants died as a result of DRM, although some of them died as
a result of TRM (supplemental Figure 7). We observed the same trend in both patients with ALL and those
with AML/MDS (supplemental Figures 8 and 9). NT5E is involved in metabolism of purine analogs, such
as fludarabine (Flu), mycophenolate mofetil (MMF), and azathioprine. Flu can be used as part of the
conditioning regimen, and MMF and azathioprine are drugs for posttransplantation immunosuppression.
We first speculated that NT5E might influence DRM through its interaction with Flu or MMF. However,
because there were only 28 recipients with corresponding donors carrying the NT5E variants, and none of
them died as a result of disease in the first year after transplantation, we were unable to test for differences
in DRM between those receiving the drug or not (data not shown). In contrast, NT5E is the enzyme for
converting extracellular adenosine monophosphate to adenosine, which suppresses antitumor T-cell
responses and therefore promotes tumor initiation and progression.22-26 Crystal structures of NT5E
revealed that the enzyme forms a homodimer and switches between the open and closed conformations in
the catalysis process27 (supplemental Figure 10). Four of the 6 variants in donors that protected patients
from death resulting from DRM after BMT were predicted to be deleterious (supplemental Table 8). By
inspecting the NT5E crystal structures, we found 4 of these mutations to have an impact on the enzyme
structure (Figure 3), which likely decreased the catalytic efficiency of the enzyme and led to enhanced
antitumor T-cell responses and lower risk of DRM.

Discussion
This study on the contribution of rare variants to BMT survival outcomes has revealed an interesting sexspecific single-variant association and a number of novel genes. Genotype mismatches between recipients
and donors in a rare variant of TEX38 (rs200092801) significantly increased the risk of TRM. The increase
of TRM risk was less dramatic when the recipients and the corresponding donors were both male. TEX38
is highly expressed in the testes with unknown function. The testes, which were previously thought to be
insulated from the immune system by the Sertoli cell barrier, were recently found to be connected with
immune system.28 In this groundbreaking study, the authors demonstrated in mice that there are
nonsequestered meiotic germ cell antigens (NS-MGCAs) that can pass through the Sertoli cell barrier and
then be recognized by antigen-specific regulatory T cells to maintain systematic tolerance to NSMGCAs.28 The better tolerance of genotype mismatches at rs200092801 when both recipients and donors
were male may therefore be related to the systematic tolerance for NS-MGCAs in males. We further
investigated why genotype mismatches at rs200092801 could affect TRM, which is a composite of mainly
immune-related causes. We speculated this could happen in a manner similar to HLA mismatches, where
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC5981168/?report=printable
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differences in antigen presentation or processing increase risk of TRM. Indeed, we found rs200092801
could induce strong binding of mutant TEX38 antigen peptides with MHC class I molecules, which
possibly triggered downstream immune response to the mutant antigens and led to TRM. Furthermore, we
also observed higher TRM frequency in the rs200092801-mismatched recipient-donor pairs when the pairs
carried HLA class I alleles that could strongly bind with the mutant TEX38 antigen. Our results support
that the increased TRM risk of allele mismatches at rs200092801 could be a result of differences in antigen
presentation induced by the variant. Another important question is how this testis antigen is recognized by
the immune system. It is likely that the TEX38 antigen is an NS-MGCA that can pass through the Sertoli
cell barrier and be recognized by MHC class I molecules in immune cells. The TEX38 antigen may also be
expressed in other cells, even cancer cells. Recently, a large number of proteins normally restricted to the
germ cells of the testes were discovered to be expressed in various cancer cells, including melanoma, liver
cancer, lung cancer, bladder cancer, and leukemia cells.29-31 These cancer/testis antigens have become
promising targets in cancer immunotherapy.32-35 Whether the TEX38 antigen is expressed in recipients’
cancer cells and whether the latter also play a role in TRM in recipients are questions that remain to be
explored. Of course, our novel findings regarding mismatches at a rare TEX38 variant increasing TRM risk
need further replication, and if replicated, additional experimental work would be necessary to determine
how this variant affects TRM.
The only recipient gene we found to be associated with OS, OR51D1, was driven by its association with
TRM. Recipients carrying 1 of the 6 mutations in OR51D1 were protected from TRM. OR51D1 belongs to
class I ORs, which may be specialized in detecting water-soluble odorants. Recently, OR51D1 and many
other class I ORs were found to be expressed in blood leukocytes, and it was suggested that these receptors
may equip the immune system to react to chemicals entering the bloodstream.36 In addition, ORs are
expressed in the white blood cells of patients with AML and may be novel therapeutic targets for AML
because OR activation leads to reduced cancer cell proliferation and/or induced apoptosis and erythrocyte
differentiation.37,38 The effect of ORs on suppressing cancer cell growth has also been documented in
liver cancer,39 prostate cancer,40,41 and non–small-cell lung cancer.42 Although the mechanism for how
OR51D1 affect TRM after BMT is not known, this novel finding identifies a new direction for potentially
reducing TRM and ultimately improving patient survival.
The finding of NT5E associated with DRM in donor genotypes is of interest because NT5E is a key
metabolic regulator of several drugs used for BMT, including Flu and MMF. We first speculated that the
effect of NT5E on DRM could be exerted through drug metabolism. However, we failed to determine
whether taking the drugs (Flu or MMF) or not resulted in any difference in the effect of NT5E on DRM,
because only 28 patients received transplants from donors carrying NT5E mutations, and in all cases, the
patients did not die as a result of DRM within the first year after transplantation. Therefore, even larger
cohorts than DISCOVeRY-BMT will be needed to evaluate whether drug usage makes any difference on
the impact of NT5E on DRM. Alternatively, NT5E might affect DRM through its catalysis of adenosine
monophosphate to adenosine, which is the major control point for extracellular adenosine levels.
Numerous studies have revealed the immunosuppressive and proangiogenic effects of extracellular
adenosine and the important role it plays in tumor onset and progression.22-26 NT5E overexpression has
been found in various cancer types22,24 and is associated with poor prognosis.43-46 We found the rare
NT5E mutations present in donors could have an impact on various aspects of enzyme activity, including
protein conformation change, dimerization, and binding with adenosine (Figure 3). Therefore, we
hypothesized that donors carrying those mutations had lower adenosine-generating efficiency, and hence,
the recipients whose donors carried the mutations experienced NT5E inhibition. Recent preclinical studies
have demonstrated that targeted blockade of NT5E can effectively inhibit tumor growth.46-55 Consistent
with the reported therapeutic effect of NT5E suppression, we observed no disease relapse in our patients
with blood cancer who received transplants from donors carrying NT5E rare mutations. This observation
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may provide clinical evidence supporting anti-NT5E therapy for patients with cancer. Future functional
studies of these rare coding mutations and additional confirmation of our findings are needed to
demonstrate this point.

Supplementary Material
The online version of this article contains a data supplement.
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Table 1.
Characteristics of the DISCOVeRY-BMT cohort
Patient characteristics

*
P

N (%)
Cohort 1 (n = 1970) Cohort 2 (n = 503)

Age, y

<.01

Mean

43.0

46.7

Range

0.45-74.5

0-78

Donor age, y

<.01

Mean

34.2

31.6

Range

18.4-61.2

18.2-60

Sex

NS

Female

858 (44)

218 (43)

Male

1112 (56)

285 (57)

Donor sex

<.01

Female

564 (32)

118 (25)

Male

1177 (68)

362 (75)

Disease

<.01

ALL

442 (22)

41 (8)

AML

1196 (61)

327 (65)

MDS

332 (17)

135 (27)

ALL disease status

NS

Early

362 (82)

33 (80)

Advanced

80 (18)

8 (20)

AML disease status

.01

Early

843 (70)

254 (78)

Advanced

353 (30)

73 (22)

MDS disease status

<.01

Early

221 (67)

46 (34)

Advanced

111 (33)

89 (66)

Graft source

<.01

Bone marrow

694 (35)

114 (23)

P i h

1276 (65)

389 (77)

l bl d

Open in a separate window
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; NS, not
significant.
*

Kolmogorov-Smirnov test was used to compare the age distribution between cohorts. Fisher’s exact test and χ2 test
weres used to compare binary and multicategorical data between the 2 cohorts.
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Table 2.
The variant in TEX38 whose allele mismatches contribute to TRM in recipients
Variant

Chromosome

Position

Alleles

rsID

AA

†
Impact Minor

*
change

(ref/alt)

‡
MAF

allele

Allele
mismat
frequen

exm56988

1

47139039

C/T

rs200092801

P178S

Tolerated

T

3.05E−03

5.17E−

MAF, minor allele frequency.
*

The amino acid changes are based on transcript NM_001145474.
Prediction of functional impact of the AA change by SIFT56 or PolyPhen2.57
‡
The MAF in recipients of cohort 1. The minor allele was not observed in recipients or donors of cohort 2.
§
The frequency of allele mismatch in recipient-donor pairs in cohort 1. This was calculated as the sum of absolute
difference in allele dosage between all recipient-donor pairs divided by 2 times the number of recipient-donor pairs.
ǁ
The MAF in the Exome Aggregation Consortium58 non-Finnish European population.
†
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Figure 1.

Estimated cumulative incidence curves with TRM and DRM as competing events for recipients with donor
genotypes with 1 allele mismatch and no mismatch of rs200092801 in cohort 1. Two allele mismatches of this variant
between recipients and donors were not observed.
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Figure 2.

Estimated cumulative incidence curves for different combinations of recipient and donor sex with TRM and DRM
as competing events for recipients with donor genotypes with 1 allele mismatch and no mismatch of rs200092801 in
cohort 1. Two allele mismatches of this variant between recipients and donors were not observed.
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Table 3.
The 6 variants in OR51D1 that contribute to the gene-level association with OS and TRM in
recipients
Variant

Chromosome Position

Alleles

rsID

AA

†
Impact

*
change

(ref/alt)

Minor

M

allele

Cohort 1 Coho

exm881159

11

4661190

C/G

rs138224979

T57S

Tolerated

G

2.54E−04

NA

exm881165

11

4661280

C/T

rs148606808

S87F

Deleterious

T

3.81E−03 4.97E

exm881174

11

4661373

A/C

rs141786655

H118P

Deleterious

C

5.08E−04 9.94E

exm881176

11

4661424

G/A

rs61745314

R135H

Deleterious

A

2.54E−04 9.94E

exm881178

11

4661451

G/A

rs200394876

R144H

Tolerated

A

1.02E−03

exm881179

11

4661457

C/T

rs149135276

A146V

Deleterious

T

7.61E−04 9.94E

NA

NA, not applicable.
*

The amino acid changes are based on transcript NM_001004751.
Prediction of functional impact of the AA change by SIFT56 or PolyPhen2.57
‡
The MAF in the Exome Aggregation Consortium58 non-Finnish European population.
†
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Table 4.
The genes significantly associated with survival outcomes in donors
Outcome

Gene

Chromosome

Pmeta

*
No. of variants

OS

ALPP

2

1.05E−06

3

EMID1

22

1.05E−06

2

SLC44A5

1

1.05E−06

2

LRP1

12

2.86E−06

27

TRM

HHAT

1

9.34E−07

6

DRM

LYZL4

3

1.05E−06

3

NT5E

6

1.05E−06

6

*

The number of single variants included in the meta SKAT-O test.
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Figure 3.

Open in a separate window
The NT5E variants in the crystal structure of the enzyme. (A) NT5E A62 (magenta) directly interacts with I320 and
K321 (yellow) in the α-helix that connects the 2 protein domains and works as a hinge for the conformational change
between the open and closed states. The A62S variant is predicted to impede the conformational change of the enzyme
from the open state to the closed state. (B) V278 (magenta), interacting with L290 and V240 (yellow), is buried within the
core of the N-terminal domain. The V278I variant is predicted to affect the folding of this domain and the conformation of
the catalytic pocket. (C) The side chain of R354 (magenta) forms a hydrogen bond with adenosine. The R354C variant is
predicted to disrupt the binding of adenosine.27 (D) R401 (magenta) interacts with R480 (yellow) from the other chain in
the closed state. The R401C variant is predicted to impede the NT5E dimerization and the conformational change of the
enzyme from the open state to the closed state. All structures shown are in the closed state. The substrate adenosine is
displayed in the sphere model, and the highlighted amino acids are displayed in the stick model.
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